No abstract

In the era when positron emission tomography (PET) seems to constitute the most advanced application of nuclear medicine imaging, still the conventional procedure of single photon emission computed tomography (SPECT) is far from being obsolete, especially if combined with computed tomography (CT). In fact, this dual modality imaging technique (SPECT/CT) lends itself to a wide variety of useful diagnostic applications whose clinical impact is in most instances already well established, while the evidence is growing for newer applications. The increasing availability of new hybrid SPECT/CT devices with advanced technology offers the opportunity to shorten acquisition time and to provide accurate attenuation correction and fusion imaging. In this review we analyse and discuss the capabilities of SPECT/CT for improving sensitivity and specificity in the imaging of both oncological and non-oncological diseases. The main advantages of SPECT/CT are represented by better attenuation correction, increased specificity, and accurate depiction of the localization of disease and of possible involvement of adjacent tissues. Endocrine and neuroendocrine tumours are accurately localized and characterized by SPECT/CT, as also are solitary pulmonary nodules and lung cancers, brain tumours, lymphoma, prostate cancer, malignant and benign bone lesions, and infection. Furthermore, hybrid SPECT/CT imaging is especially suited to support the increasing applications of minimally invasive surgery, as well as to precisely define the diagnostic and prognostic profile of cardiovascular patients. Finally, the applications of SPECT/CT to other clinical disorders or malignant tumours is currently under extensive investigation, with encouraging results in terms of diagnostic accuracy.

No abstract

No abstract

Hybrid SPECT/CTCA imaging results in improved specificity and PPV to detect hemodynamically significant coronary lesions in patients with chest pain. Single-photon emission computed tomography/CTCA might play a potentially important role in the noninvasive diagnosis of coronary artery disease and introduce an objective decision-making tool for assessing the need for interventions in each occluded vessel.

BACKGROUND. Early diagnosis of recurrent breast cancer is crucial to selection of the most appropriate therapy. The current study evaluated the role of FDG‐PET/CT in the assessment of suspected recurrent breast cancer in patients who presented with elevated serum tumor markers. METHODS. Forty‐seven consecutive FDG‐PET/CT studies of 46 women (aged 32–79 years; mean, 59.9 years) with a history of breast cancer presented with elevated serum tumor markers 1–21 years (mean = 6.2 years) after their initial diagnosis and were retrospectively evaluated. PET/CT results were confirmed by pathology (n = 11), further imaging, and follow‐up (mean = 17.2 months; n = 36). Changes in further management based on PET/CT were recorded. RESULTS. Thirty (65%) patients had tumor recurrence, and 16 (35%) patients showed no further evidence of disease. Thirty‐one patients had 32 abnormal PET/CT studies, and 15 patients had normal studies with an overall sensitivity, specificity, and accuracy of 90%, 71%, and 83%, respectively. In 37 patients, PET/CT was compared with contrast‐enhanced CT and had a higher sensitivity (85% vs 70%), specificity (76% vs 47%), and accuracy (81% vs 59%). PET/CT had an impact on the management of 24 (5l%) patients. Of these, chemotherapy or radiotherapy was started in 16 patients, treatment was modified in 2 patients, and 6 patients were referred to biopsy, followed by referral to surgery for 2 patients. CONCLUSIONS. In patients with breast cancer and rising tumor markers, FDG‐PET/CT had high performance indices and was superior to CT for diagnosis of tumor recurrence, which led to changes in the subsequent clinical management of 51% of these patients. Cancer 2006. © 2006 American Cancer Society.

IntroductionRadiolabelled autologous white blood cells (WBC) scintigraphy is being standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in many European countries radiolabelled anti-granulocyte antibodies (anti-G-mAb) are used instead of WBC with high diagnostic accuracy. The EANM Inflammation & Infection Committee is deeply involved in this process of standardization as a primary goal of the group.AimThe main aim of this guideline is to support and promote good clinical practice despite the complex environment of a national health care system with its ethical, economic and legal aspects that must also be taken into consideration.MethodAfter the standardization of the WBC labelling procedure (already published), a group of experts from the EANM Infection & Inflammation Committee developed and validated these guidelines based on published evidences.ResultsHere we describe image acquisition protocols, image display procedures and image analyses as well as image interpretation criteria for the use of radiolabelled WBC and monoclonal antigranulocyte antibodies. Clinical application for WBC and anti-G-mAb scintigraphy is also described.ConclusionsThese guidelines should be applied by all nuclear medicine centers in favor of a highly reproducible standardized practice.

This paper demonstrates a super-resolution method for improving the resolution in clinical positron emission tomography (PET) scanners. Super-resolution images were obtained by combining four data sets with spatial shifts between consecutive acquisitions and applying an iterative algorithm. Super-resolution attenuation corrected PET scans of a phantom were obtained using the two-dimensional and three-dimensional (3-D) acquisition modes of a clinical PET/computed tomography (CT) scanner (Discovery LS, GEMS). In a patient study, following a standard 18F-FDG PET/CT scan, a super-resolution scan around one small lesion was performed using axial shifts without increasing the patient radiation exposure. In the phantom study, smaller features (3 mm) could be resolved axially with the super-resolution method than without (6 mm). The super-resolution images had better resolution than the original images and provided higher contrast ratios in coronal images and in 3-D acquisition transaxial images. The coronal super-resolution images had superior resolution and contrast ratios compared to images reconstructed by merely interleaving the data to the proper axial location. In the patient study, super-resolution reconstructions displayed a more localized 18F-FDG uptake. A new approach for improving the resolution of PET images using a super-resolution method has been developed and experimentally confirmed, employing a clinical scanner. The improvement in axial resolution requires no changes in hardware.